In the front-line setting of FLT3-mutated AML, combining conventional chemotherapy with a multi-targeted tyrosine kinase inhibitor (TKI), namely midostaurin, resulted in improved overall survival (9). Here, FLT3 is linked to acute myeloid leukemia.